Medicus Pharma Ltd. Warrant

Medicus Pharma Ltd. is a biotech and life sciences company focused on clinical development programs for therapeutic assets in the United States. It is developing SKNJCT-003, which is in a Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access SKINJECT in patients with Gorlin Syndrome. Formerly known as Interactive Capital Partners Corporation, it changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.